drugset / Trial / NCT01746901

A Study to Characterize the Abuse Liability of ALO-02 in Healthy, Non-Dependent, Recreational Opioid Abusers

NCT01746901

Phase 1 Completed 81 enrolled Pfizer Syneos Health · collab
RandomizedCrossoverDouble-blindOther

Summary

The main purpose of this study is to determine if oxycodone and naltrexone combination capsules (ALO-02) have the potential to be abused.

Timeline

Start
2013-02
Primary completion
2013-08-09
Completion
2013-08-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Naltrexone Small molecule 4.8 mg Oral
Subject Naltrexone Small molecule 7.2 mg Oral
Comparator Oxycodone Other / unclassified 40 mg Oral
Comparator Oxycodone Other / unclassified 60 mg Oral

Indications

No indication recorded.